[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Cincinnati\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":620},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,42,64,86,112,135,166,198,229,247,269,294,311,339,362,384,405,426,444,469,502,527,548,573,600],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100633588","intraoperative-neuromonitoring-ionm-and-bipolar-electrocautery-be-during-axillary-lymph-node-dissection-alnd-100633588",false,"NCT07528638","Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND)","Feasibility of Using Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) to Provide Early Identification and Protection of the Intercostalbrachial Nerve (ICBN), Medial Branch Cutaneous Nerve (MBCN), and Their Branches","Inclusion Criteria:\n\n1. Patients ages 18-70 years old.\n2. Pathologically confirmed diagnosis of breast cancer.\n3. Undergoing ALND by one of the breast surgeon Sub-Investigators on this study.\n\nExclusion Criteria:\n\n1. Patients having any previous axillary surgery other than percutaneous breast biopsy and\u002For SLNB.\n2. Prior breast radiation with neuropathy clearly developing after radiation.\n3. Patients who have undergone prior chemotherapy and developed post-chemotherapy neuropathy prior to ALND.\n4. Patients with any pre-existing neurological conditions affecting nerves, such as neuropathy (peripheral neuropathy, neuropathic pain or nerve injury to upper extremity).\n5. Patients taking medications that are known to modify neuropathic pain (eg, gabapentin, pregabalin, duloxetine, venlafaxine, lidocaine patches, capsaicin, opioids, tramadol, NMDA receptor antagonists, clonidine, cannabis, botox).\n6. Patients with prior spinal surgery or spinal pathology (cervical spinal stenosis or cervical radiculopathy).\n7. Patients with limb-dysfunction.\n8. Patients with demyelinating disease.\n9. Patients with significant co-morbidities (clotting disorders on anticoagulation, cardiac issues, other conditions that could impact long-term follow-up).\n10. Patients that present with pre-operative breast, arm or chest pain ipsilateral to anticipated ALND.\n11. Patients who have had prior procedures where IONM failed intraoperatively.\n12. Presence of parietal cortical lesion.","ALL","18 Years","70 Years",{"count":21,"type":22},6,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to determine whether the implementation of existing neurosurgical techniques of intraoperative neuromonitoring (IONM) and the replacement of monopolar electrocautery with bipolar electrocautery (BE), during ALND, will improve the early identification of nerves that have been implicated in the cause of neuropathically-mediated post-surgical pain syndrome (PSPS).",[28,29],"Breast Cancer","Surgery","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":31,"type":34},{"date":37,"type":22},"2027-12-01",{"name":39,"class":40},"University of Cincinnati","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100609388","phase-1-phase-i-ii-trial-combining-pd-1-inhibition-and-neoadjuvant-proton-or-photon-radiation-therapy-in-recurrent-head-and-neck-squamous-cell-carcinoma-100609388","NCT07213934","Phase I\u002F II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma","WOPPPR: Window of Opportunity Phase I and Phase II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma","Inclusion Criteria (Both Phase I and Phase II)\n\n1. Patients must have histologically or cytologically confirmed recurrent head and neck squamous cell carcinoma including oral cavity, laryngeal, hypopharyngeal, or oropharyngeal (HPV-) SCC.\n2. Patients must be a candidate for salvage surgical resection.\n3. Patients must have failed prior RT \\>6 months prior to recurrence with at least 30 Gy delivered to the current target volume.\n4. Disease must be limited to a single site or adjacent sites that can be treated in a single contiguous target volume for which the maximum total tumor dimension (GTV) must be \\\u003C7 cm.\n5. Patients must have a CPS PD-L1 of ≥1%. This may be tested on a new biopsy or archival tissue.\n6. Age ≥18 years.\n7. ECOG performance status ≤1 (or Karnofsky ≥70%, see Appendix A).\n8. Patients must have adequate organ and marrow function as defined below:\n\n   Platelets ≥100,000\u002FmcL Total bilirubin ≤ institutional upper limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN Creatinine ≤ 1.5x institutional upper limit of normal (ULN) OR glomerular filtration rate (GFR) ≥30 mL\u002Fmin\u002F1.73 m2 (see Appendix B).\n9. Archival tissue must be available for baseline analysis. Either a tumor block or at least 20 slides must be available.\n10. Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n11. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n12. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n13. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n14. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n15. Women of child-bearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of pembrolizumab administration.\n16. Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria (Phase I \\& II)\n\n1. Patients who have metastatic disease.\n2. Patients who have ongoing adverse events from prior anti-cancer therapy that would preclude completion of the proposed study treatment at the opinion of the treating investigators.\n3. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI.\n4. Prior treatment with PD-1 inhibitors in the last 6 months or progression on a PD-1 inhibitor at any time.\n5. Autoimmune disease or other pro-inflammatory conditions other than treated stable asthma, minor allergies (such as seasonal allergies), vitiligo or hypothyroidism.\n6. Active and ongoing steroid use \\>10 mg prednisone, except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, COPD, allergic rhinitis).\n7. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.\n8. Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with breastfeeding should be discontinued if the mother is treated with pembrolizumab.",{"count":50,"type":22},40,[52,53],"PHASE1","PHASE2","The purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC).\n\nThe purpose of the Phase II study is to see if using XRT or PT before immunotherapy (pembrolizumab) prior to surgery benefits patients with recurrent head and neck squamous cell carcinoma (rHNSCC).",[56,57],"Head and Neck Cancer","Recurrent Head and Neck Squamous Cell Carcinoma",{"date":33,"type":34},{"date":60,"type":34},"2025-10-08",{"date":62,"type":22},"2031-12",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100614068","safety-and-effectiveness-of-navifus-system-with-bevacizumab-in-recurrent-glioblastoma-100614068","NCT07274787","Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma","An Open Label, Prospective, Pilot Study To Evaluate The Safety And Effectiveness Of The NaviFUS System In Conjunction With A Standard Treatment Regimen Of Bevacizumab (BEV) In Patients With Recurrent Glioblastoma","Inclusion Criteria:\n\n1. Adult male\u002Ffemale patients ≥ 18 years of age.\n2. Histologically confirmed glioblastoma at original diagnosis, recurrent after prior radiotherapy and temozolomide chemotherapy.\n3. Must have measurable disease ≥ 10mm (according to RANO criteria) .\n4. Interval since completion of radiation treatment (including radiation at original diagnosis and\u002For radiation for recurrent disease) ≥ 12 weeks.\n5. If on steroids, must be on a stable dose for ≥ 7 days prior to study treatment.\n6. Body mass index (BMI) ≥17 kg \u002F m2.\n7. Minimum interval since last drug therapy:\n\n   1. 1 week for non-cytotoxic agents (e.g., interferon, tamoxifen), daily chemotherapy (e.g., metronomic temozolomide, cytoxan) or targeted therapies administered daily (e.g., gleevec, tarceva).\n   2. 4 weeks since last cytotoxic therapy.\n   3. 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen (e.g., carmustine).\n8. Life expectancy ≥ 12 weeks.\n9. KPS Score \\> 60.\n10. Adequate hepatic, renal, coagulation, and hematopoietic function:\n\n    1. Hemoglobin ≥ 8 g\u002FdL.\n    2. Platelets ≥ 100,000\u002Fmm3.\n    3. Neutrophils ≥ 1,500\u002Fmm3.\n    4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN).\n    5. Urine protein creatinine (UPC) ratio \\\u003C 1 or urine dipstick for proteinuria ≤ 2+.\n    6. Alanine transaminase (ALT) \\\u003C 3 x ULN.\n    7. Aspartate transaminase (AST) \\\u003C 3 x ULN.\n    8. Prothrombin time ≤ 1.2 x ULN.\n    9. International Normalized Ratio (INR) \\\u003C 1.5.\n    10. Bilirubin \\\u003C 2 x ULN.\n11. Center of region of interest (ROI) (i.e., tumor site) ≥30mm deep to skull bone.\n12. If there is the potential for pregnancy, must agree to follow acceptable birth control methods to avoid conception.\n13. Able and willing to have their hair shaved (either whole head or the region where the coupling membrane will touch) and placement of peripheral IV line prior to treatment.\n\nExclusion Criteria:\n\n* 1\\) Previous treatment with an inhibitor of vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR), including bevacizumab.\n\n  2\\) New York Heart Association (NYHA) Grade II or greater congestive heart failure requiring hospitalization within 12 months prior to screening.\n\n  3\\) Hypertension (systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg).\n\n  4\\) Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, severe cerebral or myocardial infarction, cardiac shunt, heart attack within the previous 12 months, stroke (except for transient ischemic attack; TIA) within the previous 6 months, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n\n  5\\) Unstable Pulmonary Disease or Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of screening.\n\n  6\\) Implanted pacemaker, defibrillator or deep brain stimulator, or other implanted electronic devices in the brain or documented clinically significant arrhythmias.\n\n  7\\) Major surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open biopsy or significant traumatic injury ≤ 4 weeks prior to screening, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤ 1 week prior to screening, or who have not recovered from side effects of such procedure or injury.\n\n  8\\) Known human immunodeficiency virus (HIV) positivity.\n\n  9\\) Acute bacterial or fungal infection requiring intravenous antibiotics at the time of screening.\n\n  10\\) Pregnant or breast-feeding women.\n\n  11\\) Known sensitivity\u002Fallergy to MRI contrast agents, CT contrast agents, SonoVue® \\[Lumason®\\], bevacizumab, or any of their components.\n\n  12\\) Abnormal baseline findings considered by the Investigator to indicate conditions that might affect study endpoints.\n\n  13\\) Hemorrhage or cyst within the ROI.\n\n  14\\) ROI in the deep center brain with crucial brain functions, such as in the region of the brain stem.\n\n  15\\) The receipt of an investigational drug within a period of 4 weeks prior to the first FUS exposure.\n\n  16\\) Use of any recreational drugs or a history of drug addiction.\n\n  17\\) Difficulty lying supine and still for the FUS procedure length.\n\n  18\\) Any other condition that, in the Investigator's judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.",{"count":72,"type":22},10,[25],"This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.",[76],"GBM","NOT_YET_RECRUITING","2026-06-02",{"date":80,"type":34},"2026-06-04",{"date":82,"type":22},"2026-12-01",{"date":84,"type":22},"2029-12-01",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100583038","early-neuromodulation-in-traumatic-brain-injury-100583038","NCT06871124","Early Neuromodulation in Traumatic Brain Injury","Early Neuromodulation for Cognitive Recovery and Rehabilitation in Traumatic Brain Injury","Inclusion Criteria:\n\n1. Moderate to severe TBI: Glasgow Coma Scale (GSC) in the 3-12 range and greater than 30 min of loss of consciousness and\u002For a post-traumatic amnesia that lasts more than 24 hours and\u002For an alteration of mental state over 24 hours,\n2. age 18-80 years,\n3. Isolated TBI,\n4. Intelligible speech and Galveston Orientation and Amnesia Test (GOAT) score \\>70 at time of enrollment.\n\nExclusion Criteria:\n\n1. Persistent bilateral non-reactive pupils or other evidence of non-survivable injury,\n2. Decompressive craniectomy to treat refractory ICP subsequent to diffuse injury, (3) Co-enrollment in another therapeutic TBI trial,\n\n(4) Pregnancy, (5) Patients with polytrauma (6) Patients with clinical seizures or status epilepticus.","80 Years",{"count":95,"type":22},60,[25],"The two goals of the proposed study are: (1) To determine how brain activity changes with cognitive recovery over time from acute to chronic phases of traumatic brain injury (TBI). (2) To determine how the time of anodal transcranial electrical stimulation (A-tES) administration affects cognitive performance and brain activity in TBI.\n\nTo achieve these study goals, the investigators will conduct a pilot clinical trial over three years in which the investigators aim to recruit 60 patients with moderate to severe TBI at the University of Cincinnati Medical Center (UCMC). During the acute phase of TBI, all participants will complete clinical questionnaires and perform 2 cognitive computer tasks while their brain activity is recorded. Half of the participants will be randomly selected to receive A-tES for 15 minutes while performing cognitive tasks and the other half will receive sham stimulation. All participants will be followed for 6 months. During their 3-month follow-up, the investigators will perform another session where all participants complete the questionnaires and receive A-tES while performing cognitive tasks during brain recording. In their last visit at 6 months post-injury, all participants will complete the questionnaires and cognitive tasks with brain recording but no stimulation treatment. From the collected data, the investigators will determine if time from brain injury correlates with brain activity during performance of cognitive tasks. The investigators will also assess the efficacy of early A-tES treatment for improving cognitive task performance and clinical test ratings at 6 months post-injury in comparison to A-tES delivered during the 3-month follow-up visit.",[99],"Traumatic Brain Injury (TBI) Patients",[101,102,103,104],"transcranial electrical stimulation","cognitive control","working memory","EEG",{"date":106,"type":34},"2026-06-03",{"date":108,"type":34},"2025-06-16",{"date":110,"type":22},"2028-04-30",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":17,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":21},"100459878","neuroimaging-reveals-treatment-related-changes-in-dld-100459878","NCT05268341","Neuroimaging Reveals Treatment-related Changes in DLD","Inclusion Criteria:\n\n* ages 48-71 months\n* average nonverbal intelligence quotient (IQ)\n* enrolled in participating center\n* typically developing (receptive and expressive language, social, articulation, other)\n* DLD for expressive grammar\n* typical oral motor function\n* typical social\u002Fpragmatics skills\n* average hearing thresholds\n* monolingual and native Standard English speakers\n* does not have any uncorrected vision challenges\n\nExclusion Criteria:\n\n* receiving co-occurring speech-language or other intervention for communication\n* not MRI safe\n* special education placement of child based on ability or behavior",true,"48 Months","71 Months",{"count":122,"type":22},100,[25],"Children with developmental language disorders (DLD, aka specific language impairment), a prevalent pediatric disorder, experience hallmark grammar deficits with life-long impacts on educational and occupational outcomes. While effective and early interventions can mitigate the impact of DLD, not enough is known about the neural basis of DLD in young children, yet is needed to inform the design of more individualized interventions. This project uses neuroimaging, along with behavioral methods, with the goal of better understanding the memory-language mechanisms that underlie grammar learning and impairment, while also considering their association to treatment-related changes in preschoolers with DLD.",[126],"Developmental Language Disorder","2026-05-20",{"date":129,"type":34},"2026-05-26",{"date":131,"type":34},"2022-05-24",{"date":133,"type":22},"2027-06-30",{"name":39,"class":40},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":154,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":143,"type":22},30,[52],"Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[147,148,149,150,151,152,153],"Sickle Cell Disease","Cognitive Impairment","Cognitive Decline","Cognitive Change","Cognitive Dysfunction","Cognitive Deficit","Neuroinflammatory Response",[155,156,157,158],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","2026-05-11",{"date":161,"type":34},"2026-05-14",{"date":82,"type":22},{"date":164,"type":22},"2028-06-15",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":41},"100577219","phase-1-modulating-spinal-interoceptive-pathways-to-evaluate-their-role-and-therapeutic-potential-in-mdd-symptomatic-domains-100577219","NCT06795451","Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains","MOSPID","Inclusion Criteria:\n\n* 18 to 60 yrs., inclusive,\n* Female or Male,\n* With current MDD episode according to MINI 7.0.2. duration (≥4 weeks and\n\n  ≤ 2 yrs.),\n* Current BMI ≥18.5 and ≤ 35.99 kg\u002Fmts2\n* MADRS score at screening ≥18\n* Currently on an FDA- approved antidepressant medication at a stable therapeutic dose for ≥ 8 weeks,\n* Psychotherapeutic interventions are allowed if dose\u002Ffrequency stable for ≥4 weeks,\n* Anxiety disorders allowed if no more than moderate in severity and are not the main diagnosis,\n* Using an effective contraceptive method (participants with childbearing potential), and 10)Able to complete study related tasks.\n\nExclusion Criteria:\n\n* Treatment resistance during current depressive episode (\\>2 treatment trials at adequate doses\u002Fduration), including medication and neuromodulation treatments.\n* Current\u002Flifetime diagnosis of bipolar disorder or schizophrenia spectrum disorders.\n* Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year.\n* Psychotic symptoms during the current MDD episode or in the past 6 months.\n* Current (past month) substance use disorder (nicotine, caffeine allowed).\n* Current unstable neurological conditions including seizure disorders (infantile seizures are not exclusionary), neurodegenerative disorders, or stroke.\n* Evidence of severe peripheral neuropathy.\n* History of moderate to severe traumatic brain injury (e.g., skull fracture or loss of consciousness \\>10 minutes) or spinal cord injury.\n* Unstable clinically significant medical conditions (e.g., uncontrolled hypertension as indicated by a systolic \\>150 mmHg or diastolic \\>95mmHg).\n* History of cancer allowed if remitted for the past 5 years.\n* Use of anticonvulsant medications and calcium channel blockers at screening.\n* Current severe pain conditions or need for chronic use of pain medication including NSAIDs and opiates.\n* Implanted electronic medical devices.\n* Neuromodulation interventions in the past month.\n* Active skin lesions on electrode placement sites.\n* pregnant or breastfeeding.\n* Suspected IQ \\\u003C80.\n* Any other relevant clinical reason as judged by the clinician.","60 Years",{"count":175,"type":22},67,[52,53],"Spinal interoceptive pathways (SIPs) convey bodily signals to an interoceptive system in the brain and their dysregulation is linked to major depressive disorder (MDD). Current treatments are partially effective and the role of SIPs in MDD is vastly unexplored. Preliminary data suggests that SIPs are feasible therapeutic targets in MDD. The central hypothesis is that non-invasive spinal cord stimulation will modulate SIPs to elucidate their role and therapeutic potential in MDD using an R61\u002F33 phased innovation approach.\n\nR61 phase specific aims (SA). The specific goal will be to evaluate spinal and brain-based SIPs target engagement markers of transcutaneous spinal direct current stimulation (tsDCS) in MDD with two SAs: SA1) To determine tsDCS SIPs modulation using laser-evoked potentials (LEPs) as electroencephalography (EEG)- based neural measures of target engagement. SA2) To evaluate optimal tsDCS dose based upon tolerability and SIPs target engagement markers. Anodal tsDCS will be evaluated as a tool to modulate SIPs in MDD. SIPs (Aδ and C fibers) can be evaluated via LEPs as neural measures (EEG) elicited in MDD-relevant brain regions within an interoceptive system. Prior data shows anodal tsDCS inhibits SIPs and LEPs N2 component will be assessed as tsDCS engagement markers. Adults with MDD (n=67) will participate in a double-blind, crossover, sham-controlled study to evaluate tsDCS at 0,2.5,3, and 3.5 mA. The working hypothesis is that tsDCS will induce a change in LEPs (SA1) in a dose-dependent and tolerable manner (SA2), supporting their use as SIPs engagement markers. Go\u002FNo-Go milestones: Compared to sham, the active tsDCS dose that induces a change in LEPs at a preestablished threshold will be evidence of SIPs engagement and \"Go\" criteria for the R33 phase.",[179],"Depression - Major Depressive Disorder",[181,182,183,184,185,186,187,188,189],"depression","non-invasive","neuromodulation","spinal stimulation","transcutaneous spinal direct current stimulation","major depressive disorder","interoception","spinal interoceptive pathways","laser-evoked potentials","2026-04-28",{"date":192,"type":34},"2026-05-04",{"date":194,"type":34},"2025-02-25",{"date":196,"type":22},"2026-07-31",{"name":39,"class":40},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":41},"100548055","phase-2-lattice-radiotherapy-for-dose-escalated-palliation-of-bulky-tumors-100548055","NCT06416007","Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors","Inclusion Criteria:\n\n* Solid tumor malignancy with a clinical indication for radiation\n* Patients must have measurable disease\n* Target lesion(s) which are amenable to lattice therapy plan\n* When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy\n* Age ≥18 years.\n* ECOG Performance status ≤2\n* Life expectancy greater than 3 months\n* Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.\n* Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.\n* Patients with a history of conditions which predispose them to increased radiation toxicity\n* Patients with known contraindications to radiation therapy\n* Patients with uncontrolled intercurrent illness\n* Pregnant women",{"count":206,"type":22},37,[53],"The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.",[210,211,212,213,214],"Cancer","Metastatic Cancer","Locally Advanced","Locally Advanced Solid Tumor","Locally Advanced Carcinoma",[216,217,218,219,220,221,222],"Radiation","Radiotherapy","Bulky","Spatial fractionation","Lattice therapy","Palliative","Palliation",{"date":192,"type":34},{"date":225,"type":34},"2024-08-02",{"date":227,"type":22},"2027-06-01",{"name":39,"class":40},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100547560","rim-plate-to-buttress-plate-for-posterior-wall-acetabular-fractures-with-and-without-inter-fragmentary-screws-100547560","NCT06409559","Rim Plate to Buttress Plate for Posterior Wall Acetabular Fractures With and Without Inter-fragmentary Screws","A Randomized Prospective Study Comparing Rim Plate to Buttress Plate for Posterior Wall Acetabular Fractures With and Without Inter-fragmentary Screws","Inclusion Criteria:\n\n1. Skeletally mature males and females, ≥ 18 years old and with age less than 65 years.\n2. Fracture of the acetabular posterior wall fracture due to acute traumatic hip dislocation, confirmed with anteroposterior pelvic or hip radiographs, and CT scan\n3. Operative fixation of fractures within 14 days of presenting to the emergency room.\n4. Patient was ambulatory prior to fracture, with or without walking aids\n5. Medically optimized for operative intervention\n6. Provision of informed consent by patient or legal guardian.\n\nExclusion Criteria:\n\n1. Patients not suitable for internal fixation (severe osteoarthritis, rheumatoid arthritis, or pathologic fracture).\n2. Pre-existing orthopedic fixation, implant, or prosthesis around the affected acetabulum.\n3. Patients with metabolic bone disease including diagnosis of osteoporosis.\n4. Patients with bony or soft tissue infections around the acetabulum.\n5. Patients unable to provide informed consent.\n6. Patients having other fractures of Pelvis or acetabulum other than an isolated posterior acetabular wall fracture.\n7. Patients with previous history of acetabular fracture (operative or nonoperative)\n8. Patients with previous history of hip pathology such as avascular necrosis, hip dysplasia, Legg-Calve Perthes Disease, or advanced degenerative arthritis.",{"count":95,"type":22},[25],"The hypothesis of this study is that the Rim Plate method utilizing interfragmentary screws placed through the plate will result in superior fixation, a lower rate of loss of reduction of the fracture fragment, better anatomic healing of the articular (joint) surface, a decreased rate of early post-traumatic arthritic changes of the joint (cartilage) surface, and improved functional outcomes.",[240],"Acetabular Fracture",{"date":192,"type":34},{"date":243,"type":34},"2023-08-01",{"date":245,"type":22},"2028-03",{"name":39,"class":40},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100506578","increased-home-based-physical-therapy-adherence-using-band-connects-virtuacare-platform-100506578","NCT05876208","Increased Home-based Physical Therapy Adherence Using BAND Connect's VirtuaCare™ Platform","Measuring the Effectiveness of BAND Connect's VirtuaCare™ Asynchronous Telerehabilitation Platform in Increasing Patient Adherence for Total Shoulder Arthroplasty and Rotator Cuff Repair Physical Therapy Rehabilitatio","Inclusion Criteria:\n\n* Dr. Brian Grawe will perform surgery, and participants will be undergoing post-operative physical therapy rehabilitation at UC Health.\n* Primary total shoulder arthroplasty and primary reverse total shoulder arthroplasty or Primary rotator cuff repair\n* Outpatient physical therapy prescribed by the doctor for post-operative rehabilitation\n\nExclusion Criteria:\n\n* Unplanned surgical procedure\n* Partial shoulder replacement or revision shoulder replacement\n* Revision rotator cuff repair\n* Fracture surgeries\n* Prior surgery within the last 5 years or less than 6 months between surgery on opposite shoulder\n* Length of stay in hospital greater than 3 days\n* Comorbidity: Uncontrolled diabetes patients; Diagnosed with cancer in the past 5 years or active disease; Any comorbidity that may impact compliance with the study protocol (completion of standard physical therapy rehabilitation procedures)\n* Injuries related to workers' compensation\n* Injuries involved in any pending litigation",{"count":95,"type":22},[25],"This study aims to enhance at-home therapy by introducing a new device called the BAND Connect's VirtuaCare™ platform. The study aims to determine whether patients can improve their adherence to at-home exercises using this device. Currently, research indicates that only 35% of patients undergoing physical therapy treatment fully comply with their prescribed plans of care, often neglecting their at-home exercises. To address this issue, a set of smart exercise tools called VirtuaCare™ has been developed. This platform provides patients with instructions on performing at-home exercises and offers real-time biofeedback to help them adjust their form if necessary. The study seeks to evaluate the effectiveness of BAND CVCP in assisting patients and improving their overall success with at-home therapy.",[258],"Shoulder Injuries",[260,261],"Rotator Cuff Repair","Anatomic and Reverse Total Shoulder",{"date":263,"type":34},"2026-04-29",{"date":265,"type":34},"2022-07-05",{"date":267,"type":22},"2027-07-31",{"name":39,"class":40},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":293},"100482318","phase-1-study-to-evaluate-the-safety-and-efficacy-of-am3101-to-augment-meniscal-healing-100482318","NCT05560477","Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing","A Prospective, Randomized, Controlled, Double-Blinded, Multi-Center, Phase 1\u002F2b Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing","Inclusion Criteria:\n\n1. Male or female ≥ 18 and ≤ 40 years old at time of screening.\n2. MRI evidence of ACL plus meniscus tear, or isolated meniscus tear.\n3. Body mass index (BMI) ≤ 40 kg\u002Fm2.\n4. Liver and kidney function panels within normal ranges at time of screening\n5. Willing and able to comply with the study procedures and visit schedule, and able to follow oral and written instructions.\n6. Willing and able to sign an IRB approved informed consent\n\nExclusion Criteria:\n\n1. Have any concomitant ligament injury requiring surgical repair or reconstruction other than the ACL.\n2. Have a history of previous meniscus injury that currently needs to be treated or has been treated surgically.\n3. Have evidence of arthritis ≥ Grade III (Outerbridge classification) in the affected compartment or greater than Kellgren Lawrence Grade 3.\n4. Elevated AST or ALT liver enzymes at time of screening\n5. Pregnant or nursing mothers, or women planning on getting pregnant during the time they will be participating in the study.\n6. Known drug or alcohol dependence currently or within the last year.\n7. Participating concurrently in another clinical study or have participated in a clinical study within the last 90 days, or intend to during the course of the study.\n8. Any medical condition or other circumstances that might interfere with the ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate postoperative rehabilitation.\n9. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the investigational product's safety and efficacy.\n10. Known allergic reaction to simvastatin.\n11. Patients currently taking simvastatin, or any other drug that is within the statin drug classification family.","40 Years",{"count":278,"type":22},74,[52,53],"The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.",[282],"Meniscus Tear",[284,285,286],"meniscal repair","complications","morbidities",{"date":192,"type":34},{"date":289,"type":34},"2023-04-26",{"date":291,"type":22},"2027-06",{"name":39,"class":40},3,{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":41},"100392419","continuous-passive-motion-following-fixation-of-pelvic-and-knee-fractures-100392419","NCT04389749","Continuous Passive Motion Following Fixation of Pelvic and Knee Fractures","The Role of Continuous Passive Motion in Pain Control of Patients Undergoing Operative Management of Isolated Acetabular Fractures, Supracondylar Femur Fractures, or Tibial Plateau Fracture: A Comparative Study","Inclusion Criteria:\n\n* Age 18 or greater\n* Isolated acetabular fractures, supracondylar femur fractures, or tibial plateau fracture\n* Have undergone operative intervention for fracture\n\nExclusion Criteria:\n\n* Injury to either lower extremity that affects the patient's ability to weight bear\n* Under the age of 18\n* Pregnant\n* A prisoner",{"count":122,"type":22},[25],"The investigators will directly compare the visual analog scale scores and narcotic pain medication requirements in the patients who have continuous passive motion (CPM) versus those who do not during the course of the hospital admission following an open reduction internal fixation surgery for acetabular fracture, supracondylar femur fracture, or a tibial plateau fracture.",[305],"Fractures, Bone",{"date":192,"type":34},{"date":308,"type":34},"2020-10-06",{"date":291,"type":22},{"name":39,"class":40},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":293},"100536685","hit-stroke-trial-2-100536685","NCT06268041","HIT-Stroke Trial 2","Moderate-Intensity Exercise Versus High-Intensity Interval Training to Recover Walking Post-Stroke: HIT-Stroke Trial 2","HST2","Inclusion Criteria:\n\n* Age 30-85 years at time of consenting\n* Hemiparesis from ischemic and\u002For hemorrhagic strokes\n* Most recent stroke for which participant sought treatment, at least 6 months prior to study consent\n* Walking speed \\\u003C1.0 m\u002Fs on the 10-meter walk test\n* Able to walk 10m over ground with assistive devices as needed and no continuous physical assistance from another person (guarding and intermittent assistance for loss of balance allowed)\n* Able to walk at least 3 minutes on the treadmill at ≥0.13m\u002Fs (0.3 mph)\n* Stable cardiovascular condition (AHA class B, allowing for aerobic capacity \\\u003C6 metabolic equivalents)\n* Able to communicate with investigators, follow a 2-step command and correctly answer consent comprehension questions\n\nExclusion Criteria:\n\n* Exercise testing uninterpretable for ischemia or arrhythmia (e.g. resting ECG abnormality that makes exercise ECG uninterpretable for ischemia and no other clinical testing from the past year available to rule out these conditions)\n* Evidence of significant arrhythmia or myocardial ischemia on treadmill ECG graded exercise test in the absence of recent (past year) more definitive clinical testing (e.g. stress nuclear imaging) with negative result\n* Hospitalization for cardiac or pulmonary disease within past 3 months\n* Implanted pacemaker or defibrillator with an upper heart rate limit that would interfere with exercise testing or prescription, or with unknown limit\n* Significant ataxia or neglect (score of 2 on NIH stroke scale item 7 or 11)\n* Severe lower limb spasticity (Ashworth \\>2)\n* Known recent history (\\\u003C3 months) of unstable substance abuse or unstable mental illness\n* Major post-stroke depression (Patient Health Questionnaire \\[PHQ-9\\] ≥ 10) in the absence of depression management by a health care provider\n* Currently participating in physical therapy or another interventional study targeting walking function\n* Recent (\\\u003C2 weeks) or planned changes in lower limb orthotic or spasticity management\n* Foot drop or lower limb joint instability without adequate stabilizing device, as assessed by a physical therapist\n* Clinically significant neurologic disorder other than stroke or unable to walk outside the home prior to stroke\n* Unable to walk outside the home prior to stroke\n* Other significant medical condition likely to limit improvement or jeopardize safety as assessed by a physical therapist (e.g. joint contracture, gait limited by pain)\n* Pregnancy\n* Previous exposure to fast treadmill walking (\\>3 cumulative hours) in the past year","30 Years","85 Years",{"count":322,"type":22},156,[25],"People who had a stroke at least 6 months prior and who still have difficulty with walking will each be randomly assigned to receive either moderate or vigorous intensity walking exercise. Both protocols will be performed individually with a physical therapist for 45 minutes, 3x\u002Fweek for 12 weeks. Measures including walking function will be assessed at baseline (PRE), after 4, 8 and 12 weeks of training (12WK) and at 3-month follow up (3moPOST), by raters who are unaware of the participant randomization.",[326],"Stroke",[328,329,330],"gait","aerobic","locomotion","2026-04-27",{"date":333,"type":34},"2026-05-01",{"date":335,"type":34},"2024-02-09",{"date":337,"type":22},"2028-04",{"name":39,"class":40},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":345,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100627381","early-pelvic-floor-physical-therapy-for-women-undergoing-pelvic-radiation-for-gynecologic-malignancies-100627381","NCT07447895","Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies","Inclusion Criteria:\n\n1. Participants must be female.\n2. Patients must be 18 years old or older.\n3. Any patient with invasive cervical cancer who is planned for definitive chemoradiation.\n4. Plan to receive a minimum dose of 45Gy to pelvis per investigator.\n5. Willing to undergo pelvic floor physical therapy.\n\nExclusion Criteria:\n\n1. Any previous therapeutic pelvic radiation.\n2. Non-English speaking.","FEMALE",{"count":347,"type":22},28,[25],"This is a single arm phase II study in which 28 patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy.",[351,352,353],"Cervical Cancer","Radiation Therapy Complication","Pelvic Floor Disorders","2026-04-20",{"date":356,"type":34},"2026-04-23",{"date":358,"type":34},"2026-04-16",{"date":360,"type":22},"2030-04-16",{"name":39,"class":40},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":371,"phases":4,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":7},"100509295","treatment-with-endovascular-intervention-for-stroke-patients-with-existing-disability-100509295","NCT05911568","Treatment With Endovascular Intervention for STroke Patients With Existing Disability","TESTED","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset\n3. Presenting to study hospital within 24 hours of last known well time\n4. Diagnosis of acute ischemic stroke\n5. Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram\n6. Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4\n7. Presenting NIH Stroke Scale score ≥6\n8. Informed consent from patient if competent or from legally authorized representative\n\nExclusion Criteria:\n\n1. Known diagnosis of a terminal cancer or terminal illness at the time of stroke\n2. Assessment of pre-stroke functional status cannot be performed during the hospital stay\n3. Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)",{"count":370,"type":22},1060,"OBSERVATIONAL","TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.",[326,374,375],"Stroke, Acute","Stroke, Ischemic","2026-04-14",{"date":378,"type":34},"2026-04-15",{"date":380,"type":34},"2023-11-16",{"date":382,"type":22},"2028-04-15",{"name":39,"class":40},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":41},"100295151","early-phase-1-study-of-letrozole-in-recurrent-gliomas-100295151","NCT03122197","Study of Letrozole in Recurrent Gliomas","A Phase 0\u002F1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination With Standard Therapy in Recurrent High Grade Gliomas","Inclusion Criteria\n\n1. Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma with plan for resection or biopsy.\n\n   \\- Inclusion #1 for Sub-study Only: Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma.\n2. Age \\>18 years.\n3. ECOG performance status 0 -2 (Karnofsky \\>60%, see Appendix A).\n4. CBC\u002Fdifferential obtained within 28 days prior to registration on study, with adequate bone marrow function defined as follows:\n\n   * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3;\n   * Platelets ≥ 100,000 cells\u002Fmm3;\n   * Hemoglobin ≥ 8.0 g\u002Fdl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable).\n5. Adequate hepatic function, defined as follows:\n\n   * Total bilirubin \\\u003C 2 x institutional ULN within 14 days prior to registration;\n   * AST or ALT \\\u003C 3 x institutional ULN within 14 days prior to registration.\n6. Adequate renal function, defined as GFR \\> 30 ml\u002Fmin or Cr \\\u003C 1.5.\n7. Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.\n8. Imaging prior to treatment including MRI of brain (with contrast preferred but not required).\n9. Ability to understand and the willingness to sign a written informed consent document.\n10. Inclusion #10 for Sub-study Only: Measurable disease per RANO criteria within 28 days of starting treatment on this study.\n\nExclusion Criteria\n\n1. Patients may not be receiving any other investigational agents.\n2. History of allergic reactions attributed to letrozole or other agents used in study.\n\n   Exclusion #2 for Sub-study Only: History of allergic reactions attributed to letrozole or TMZ.\n3. Uncontrolled intercurrent illness including, but not limited to, ongoing significant or serious active cardiovascular disease (CHF exacerbation, unstable angina or MI in last 6 months), or infection including the diagnosis of AIDS or active hepatitis B or C infection, or psychiatric illness or medical or personal conditions that in the opinion of the investigator would limit the patient's ability to participate.\n4. Patients attempting to conceive, and pregnant or nursing women are excluded from this study.",{"count":392,"type":22},39,[394],"EARLY_PHASE1","The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.",[397],"Brain Tumor","2026-04-13",{"date":358,"type":34},{"date":401,"type":34},"2017-05-16",{"date":403,"type":22},"2027-12",{"name":39,"class":40},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":41},"100586767","promoting-adherence-to-chemotherapy-handling-guidelines-among-oncology-nurses-100586767","NCT06919653","Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses","Inclusion Criteria:\n\n* being at least 18 years old\n* able to read and speak English\n* working as an oncology nurse for at least 3 months\n* handling chemotherapy drugs at work\n\nExclusion Criteria:\n\n* None",{"count":95,"type":22},[25],"Chemotherapy exposure is a serious occupational hazard affecting oncology nurses. Oncology nurses' adherence to chemotherapy handling guidelines is essential to prevent their exposure to chemotherapy. The goal of this research is to develop, validate, and pilot test an intervention \"Workplace program to Improve Safe Handling of hazardous drugs\" (WISH), to promote adherence to chemotherapy handling guidelines among oncology nurses. The WISH intervention includes two components: an educational component and debriefing sessions on chemotherapy exposure incidents. First, the research team will use a mixed-methods approach to develop an online educational component on chemotherapy safety, establish the content validity of the educational content based on experts' evaluation, and establish the face validity of the educational content by conducting three qualitative focus group with oncology nurses (n=4-6 nurses per group) or individual interviews. Next, the research team will test the feasibility and acceptability of the intervention using a pilot randomized controlled trial with two groups of oncology nurses, an intervention group (n= 30) and a control group (n=30). We will obtain quantitative and qualitative measures of the intervention feasibility and acceptability. The output is an intervention program targeted to train nurses on safe chemotherapy handling guidelines. Findings will be disseminated through peer-reviewed publications and presentations. The intermediate outcome is the adoption of the intervention program by healthcare institutions to train nurses on chemotherapy handling guidelines. The end outcome is promoting adherence to chemotherapy handling guidelines among oncology nurses.",[415,416,417,418],"Chemotherapy Exposure","Handling Guidelines","Oncology Nurse","Adherence","2026-04-07",{"date":398,"type":34},{"date":422,"type":22},"2026-06",{"date":424,"type":22},"2027-08",{"name":39,"class":40},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":319,"maxAge":93,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":443,"locationsCount":41},"100630993","measurement-properties-of-mechanical-cost-of-walking-for-individuals-with-walking-impairment-100630993","NCT07494890","Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment","Inclusion Criteria:\n\n* Age 30-80 years at the time of consent\n* Hemiparesis from ischemic and\u002For hemorrhagic strokes\n* Most recent stroke for which participant sought treatment, at least 3 months prior to study consent\n* Walking speed \\\u003C1.0 m\u002Fs on the 10-meter walk test\n* Able to walk 10m over ground with assistive devices as needed\n* Able to walk at least 5 minutes continuously on the treadmill ≥ 0.1 mile per hour\n* No contraindications to exercise according to ACSM guidelines\n* Able to communicate with investigators, follow a 2-step command and correctly answer consent comprehension questions\n\nExclusion Criteria:\n\n* Hospitalization for cardiac or pulmonary disease within past 3 months\n* Implanted pacemaker or defibrillator\n* Severe lower limb hypertonia (Ashworth \\>2)\n* Foot drop or lower limb joint instability without adequate stabilizing device\n* Clinically significant neurologic disorder other than stroke\n* Other significant medical condition likely to jeopardize safety (e.g. joint contracture, gait limited by pain)\n* Pregnancy",{"count":433,"type":22},18,[25],"Walking impairment following neurologic injury can increase the energy cost of walking threefold, acting as a functional barrier to independence. The goal of this cross-sectional study is to determine the measurement properties of a novel biomechanical cost of walking measure in chronic stroke capable of pinpointing the origins of movement inefficiencies. This research aims to:\n\n1. determine the convergent validity of biomechanical cost of walking with functional measures in relation to metabolic cost of walking,\n2. determine the reliability of biomechanical cost of walking in relation to metabolic cost of walking,\n3. determine the responsiveness of biomechanical cost of walking in relation to metabolic cost of walking.\n\nIndividuals with walking impairment from stroke will complete three 5-minute comfortable speed treadmill walking trials. The 3rd walking trial will be against resistance to increase cost of walking. This single session study will compare the metric properties of biomechanical cost of walking in relation to metabolic cost of walking.",[326],"2026-03-20",{"date":439,"type":34},"2026-03-27",{"date":378,"type":22},{"date":442,"type":22},"2027-03-01",{"name":39,"class":40},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":41},"100528646","early-phase-1-hormonal-responses-to-a-mixed-meal-in-people-with-cystic-fibrosis-100528646","NCT06163482","Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis","Changes in Postprandial Hormone Levels in Cystic Fibrosis Related Diabetes.","Inclusion Criteria:\n\n* Diagnosed with cystic fibrosis\n* Aged 18 to 45 years\n* Males and females of any race and ethnicity\n* Receiving highly effective CFTR modular therapy\n\nExclusion Criteria:\n\n* Transplant recipient\n* Acute lung function decline or exacerbation within the last 3 months\n* Use of systemic glucocorticoids\n* Pregnancy\n* Known liver disease that would be expected to significantly impact metabolic variable as interpreted by a study doctor\n* The presence of any other disease or condition, as interpreted by any one of the study doctors, that would be expected to confound the responses to liquid mixed meal or make participation in the study dangerous to the individual\n* People who are cognitively impaired\n* People who do not speak English\n* For CFRD patients, a daily insulin requirement that exceeds 0.8 U\u002Fkg\u002Fday\n* Any prior history of diabetic ketoacidosis.","45 Years",{"count":453,"type":22},61,[394],"In this exploratory study, the hormonal responses to a mixed meal will be examined in people with cystic fibrosis. The aim of this study is to find correlates with impaired glucose tolerance that is associated with this population.",[457],"Cystic Fibrosis",[459,460],"diabetes","cystic fibrosis","2026-03-18",{"date":463,"type":34},"2026-03-23",{"date":465,"type":34},"2023-03-28",{"date":467,"type":22},"2026-12-30",{"name":39,"class":40},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":477,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":41},"100628687","phase-3-prefrontal-glutamatergic-modulation-by-nac-and-mbct-for-depression-in-youth-100628687","NCT07464886","Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth","Prefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in Youth","NAC+MIND","Inclusion Criteria:\n\n1. age between 15 years, 0 months to 24 years, 11 months old;\n2. presenting with mild depression, defined by meeting DSM-5 criteria for a current major depressive episode, mild severity, or persistent depressive disorder, or other specified depressive disorder (depressive episode with insufficient symptoms to meet criteria for a major depressive episode);\n3. medication-naïve or medication free for at least 5 half-lives since the last use of a psychoactive medication, with the exception of stimulants for ADHD;\n4. if on ADHD stimulant medication over 2 months prior to screening, willing to maintain stimulant dose constant during the study participation;\n5. Tanner stage greater than or equal to III;\n\nExclusion Criteria:\n\n1. significant suicidal risk, defined by suicidal ideation of type 3, 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months, or any lifetime suicidal attempts;\n2. current major depressive episode, moderate or severe\n3. current or lifetime history of manic or hypomanic episodes, and\u002For diagnosis of bipolar disorder;\n4. current or lifetime history of psychotic disorders, and\u002For prior diagnosis of schizophrenia spectrum disorders;\n5. active or current substance use disorders in the last 3 months, except cannabis or alcohol use disorder, mild;\n6. diagnosis of autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorders, Tourette's syndrome\n7. any contraindication to MRI scanning;\n8. pregnancy;\n9. history of major neurological disorder (e.g, epilepsy), or head trauma with \\> 10 minutes loss of consciousness;\n10. intellectual disability (IQ less than or equal to 70), as determined by the Weschler Abbreviated Scale of Intelligence (WASI);\n11. previous participation in any mindfulness-based treatment;\n12. initiating psychotherapy within 2 months prior to screening, or planning to initiate psychotherapy during study participation; if on therapy, frequency and type should remain stable for 2 months prior to enrollment and during study participation;\n13. no current diagnosis of asthma\n14. history of allergic reaction to N-acetylcysteine","15 Years","24 Years",{"count":480,"type":22},160,[482],"PHASE3","The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.",[485],"Mild Depression",[487,488,489,490,491,492,493],"Depression","adolescent","young adult","youth","mindfulness-based cognitive therapy","N-acetylcysteine","double-blind placebo controlled","2026-03-06",{"date":496,"type":34},"2026-03-11",{"date":498,"type":34},"2026-02-26",{"date":500,"type":22},"2030-12",{"name":39,"class":40},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":41},"100552223","early-phase-1-effect-of-c-peptide-on-hypoglycemic-counterregulation-100552223","NCT06470295","Effect of C-peptide on Hypoglycemic Counterregulation","On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia","Inclusion Criteria:\n\n* BMI less than 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease",{"count":5,"type":22},[394],"Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.",[513,514],"Hypoglycemia","Type 1 Diabetes",[516,517,518],"glucagon","hepatic glucose production","C-peptide","2026-02-13",{"date":521,"type":34},"2026-02-17",{"date":523,"type":34},"2024-06-01",{"date":525,"type":22},"2028-01-01",{"name":39,"class":40},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":41},"100610746","early-phase-1-oral-5-strain-probiotic-for-gi-toxicity-mitigation-during-pelvic-radiation-100610746","NCT07231588","Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation","Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation","Inclusion Criteria:\n\n1. Patients must have histologically confirmed malignancy for which the standard of care treatment is at least 30 Gy of pelvic RT to the pelvic lymph nodes.\n\n   a. Eligible diagnoses include: i. Lower GI cancers (anal, rectal) ii. Gynecologic cancers (cervical, vulvar, vaginal, endometrial) iii. Prostate cancer with lymph node involvement\n2. Age ≥18 years.\n3. ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A).\n4. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with inflammatory bowel disease (IBD - such as Crohn's or Ulcerative Colitis).\n2. Patients who are currently receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI.\n3. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.\n4. Patients with a prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the Investigator.\n5. Patients who have received previous radiation therapy to the pelvis at any time.\n6. Patients who have not recovered from GI adverse events due to previous cancer therapy.\n7. Patients with colostomy or ileostomy.\n8. Pregnant women are excluded from this study because they cannot receive radiotherapy.\n9. Known inulin intolerance or allergies or hypersensitivity to any of the components of PGC, including:\n\n   1. Known hypersensitivity to \\>4 first-line antimicrobial therapies against Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Anaerobutyricum hallii: Penicillin, Piperacillin, Tetracycline, Amoxicillin, Ampicillin\n   2. Known hypersensitivity to \\>4 first-line antimicrobial therapies against Bifidobacterium infantis Bi-26TM: Gentamicin, Kanamycin, Streptomycin, Tetracycline, Erythromycin, Clindamycin, Ampicillin, Vancomycin\n10. Patients unable to swallow capsules.\n11. Absolute Neutrophil Count (ANC) \\\u003C 1500\u002FuL.",{"count":535,"type":22},20,[394],"This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.",[539],"Radiation Injuries","2026-02-02",{"date":542,"type":34},"2026-02-05",{"date":544,"type":34},"2026-01-29",{"date":546,"type":22},"2026-12-29",{"name":39,"class":40},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":41},"100617060","measuring-the-feasibility-and-effect-of-a-virtual-reality-cognitive-training-intervention-for-brain-cancer-survivors-100617060","NCT07313709","Measuring the Feasibility and Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors.","Inclusion Criteria:\n\n1. Low grade glioma survivors.\n2. Have mild cognitive impairment (MCI) per MoCA (defined as any score between 18 and 25).\n3. Completed all cancer treatment for their low-grade glioma (including chemotherapy, immunotherapy, radiation therapy and surgical procedures) and are now \\>30 days to 24 months from the date of last treatment.\n4. Age 18 years or older.\n5. English speaking.\n6. Able to provide consent without use of a Legally Authorized Representative\n7. Available to play the VR game or complete word search puzzles once per day for six days per week for four consecutive weeks in their home (per patient self-report).\n8. Have a reliable phone number by which they can be reached to make arrangement for testing and for follow-up calls.\n\nExclusion Criteria:\n\n* 1\\. History of serious mental or severe psychiatric illnesses (e.g., bi-polar disorder, schizophrenia etc....).\n\n  a. Note: Anxiety or depression are not exclusionary. 2. History or known neurodegenerative diseases such as Alzheimer's disease, vascular dementia or any other form of advanced neurodegenerative or neuro-cognitive diseases.\n\n  3\\. History of drug intoxication\u002Foverdose (addiction history). 4. History of acute traumatic brain injury. 5. History of stroke causing a cognitive deficit only. 6. Vision impairments including legal blindness.\n\n  a. Note: patients with corrected vision (e.g., glasses or contacts) or who are color-blind are eligible.\n\n  7\\. Incarcerated at the time of study enrollment. 8. Enrolled in another clinical trial which does not permit co-enrollment. 9. Any medical condition precluding safe use of VR headset and hand control technology, including patients with medical devices, including cardiac pacemakers, hearing aids\u002Fcochlear implants and defibrillators.\n\n  10\\. History of motion sickness per patient self-report.",{"count":50,"type":22},[25],"The study is focused on assessing the feasibility and effect of a virtual reality training intervention for improving the survivorship journey of brain cancer survivors, post-treatment. The gaming intervention is intended to reduce cognitive impairment, while increasing well-being, mental health, and quality of life.",[558],"Brain Cancer",[560,561,562,563,564],"virtual reality","cognitive impairment","brain cancer","cancer survivorship","non-invasive therapeutic medicine","2025-12-22",{"date":567,"type":34},"2026-01-02",{"date":569,"type":22},"2026-01-01",{"date":571,"type":22},"2027-05-01",{"name":39,"class":40},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":41},"100521694","k01-impacts-of-lingual-endurance-exercise-100521694","NCT06072924","K01 Impacts of Lingual Endurance Exercise","Impact of Lingual Endurance Exercise on Rehabilitation of Swallowing Impairments After Ischemic Stroke","Inclusion Criteria:\n\n* 1\\) 3-6 months since most recent diagnosis of ischemic, confirmed from clinical imaging) with or without small hemorrhagic transformation (HI-1)\n* 2\\) Have some indication of on-going swallowing issues\n* 3\\) English Speaking\n\nExclusion Criteria:\n\n* 1\\) ≤18 years of age\n* 2\\) history of dysphagia prior to or after the stroke caused by any of the following conditions: gastrointestinal disease, traumatic brain injury, head and neck cancer, surgery involving the pharynx or larynx\n* 3\\) history of other neurological disease (i.e. multiple sclerosis, ALS, Parkinson's, dementia).\n* 4\\) Medium to large hemorrhagic transformation\u002Finvolvement documented on clinical stroke imaging 5) 5) History of temporomandibular joint and muscle disorders (also known as TMJ).",{"count":581,"type":22},70,[25],"The goal of this clinical trial is to learn whether a tongue endurance exercise program can improve swallowing function in adults with dysphagia after a stroke. It also aims to explore how this exercise may affect brain structure and connectivity involved in swallowing. The main questions it aims to answer are:\n\nPrimary Aim: Does lingual endurance exercise improve swallowing function compared to a sham therapy? Secondary Aim: Does lingual endurance exercise lead to changes in brain structure or neuroplasticity, as measured by MRI?\n\nResearchers will compare a group receiving tongue endurance exercises to a sham therapy group to see whether the treatment improves tongue function, swallowing.\n\nParticipants will:\n\n* Complete a baseline swallowing assessment and MRI\n* Be randomly assigned to either the lingual exercise or sham therapy group\n* Complete 8 weeks of home-based tongue exercise therapy\n* Return for follow-up swallowing assessments\n* A subgroup of participants will complete a pre-treatment and post-treatment MRI.",[585,586,587,326],"Dysphagia","Dysphagia, Oropharyngeal","Ischemic Stroke",[589,590,591],"swallowing trouble","difficulty swallowing","swallow rehab","2025-12-16",{"date":594,"type":34},"2025-12-18",{"date":596,"type":34},"2023-09-01",{"date":598,"type":22},"2028-08-31",{"name":39,"class":40},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":608,"targetDuration":4,"studyType":23,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":41},"100465201","phase-2-improving-neurotrauma-by-depolarization-inhibition-with-combination-therapy-indict-100465201","NCT05337618","Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)","Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT): a Phase 2 Randomized, Feasibility Trial","INDICT","Inclusion Criteria:\n\n(1) clinical indication for emergency craniotomy with dural opening to treat acute TBI within 72 hr post-trauma\n\nExclusion Criteria:\n\n1. persistent bilateral non-reactive pupils or other evidence of non-survivable injury,\n2. decompressive craniectomy to treat refractory ICP subsequent to diffuse injury, (3) co-enrollment in another therapeutic TBI trial, and\n\n(4) pregnancy",{"count":609,"type":22},72,[53],"This study is a randomized Phase 2 trial to determine the feasibility of real-time electrocorticographic monitoring of spreading depolarizations (SD) to guide implementation of a tier-based protocol of intensive care therapies, aimed at SD suppression, for the management of patients who have undergone acute operative treatment of severe traumatic brain injury.",[613],"Traumatic Brain Injury",{"date":565,"type":34},{"date":616,"type":34},"2022-12-16",{"date":618,"type":22},"2027-03-20",{"name":39,"class":40},""]